Clinical Trial: NCT03594747
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2024-10-26 |
Study Overview
Brief Summary
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).
Official Title
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Tislelizumab
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
- Drug: Carboplatin
Other Study ID Numbers
- BGB-A317-307
- CTR20180292
Start Date (Actual)
2018-07-30
Primary Completion Date (Actual)
2020-09-30
Study Completion Date (Actual)
2023-04-28
Enrollment (Actual)
360
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2024-10-26 |
Study Overview
Brief Summary
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).
Official Title
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Tislelizumab
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
- Drug: Carboplatin
Other Study ID Numbers
- BGB-A317-307
- CTR20180292
Start Date (Actual)
2018-07-30
Primary Completion Date (Actual)
2020-09-30
Study Completion Date (Actual)
2023-04-28
Enrollment (Actual)
360
Study Type
Interventional
Phase
Phase 3